Barry Ticho Sells 10,000 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the completion of the sale, the insider now directly owns 51,277 shares in the company, valued at $618,913.39. This trade represents a 16.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Stoke Therapeutics Trading Up 12.1 %

NASDAQ STOK opened at $12.81 on Thursday. The business’s 50-day moving average price is $12.39 and its 200 day moving average price is $13.75. Stoke Therapeutics, Inc. has a twelve month low of $4.09 and a twelve month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05. The firm had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, research analysts anticipate that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Analyst Ratings Changes

STOK has been the topic of a number of analyst reports. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Finally, Leerink Partners initiated coverage on Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $20.83.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently modified their holdings of STOK. Lynx1 Capital Management LP raised its holdings in shares of Stoke Therapeutics by 40.3% in the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after purchasing an additional 1,488,371 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Stoke Therapeutics in the 2nd quarter worth about $19,835,000. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in shares of Stoke Therapeutics by 426.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after purchasing an additional 1,123,500 shares during the period. Logos Global Management LP purchased a new position in shares of Stoke Therapeutics in the 2nd quarter worth about $14,186,000. Finally, Marshall Wace LLP raised its holdings in shares of Stoke Therapeutics by 550.1% during the 2nd quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock valued at $15,686,000 after buying an additional 982,451 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.